Scrutinizing the Frustrating Cost of Drugs: How Rebates and Step Therapy Inflate Medicare Part D Prices-and Possible Reforms

Arthritis Rheumatol. 2020 Feb;72(2):203-205. doi: 10.1002/art.41135. Epub 2019 Dec 29.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antirheumatic Agents*
  • Biological Products*
  • Drug Costs
  • Medicaid
  • Medicare Part D*
  • United States

Substances

  • Antirheumatic Agents
  • Biological Products